We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Microneedle Patch Delivers Long-Acting Contraceptive

By HospiMedica International staff writers
Posted on 31 Jan 2019
A new study shows how a long-acting contraceptive designed for self-administration could provide a new family planning option, particularly in developing nations.

Developed by researchers at the Georgia Institute of Technology (Georgia Tech; Atlanta, GA, USA) and the University of Michigan (U-M; Ann Arbor, USA), the novel patch is made of 100 microneedles molded from a blend of polylactic-co-glycolic acid (PLGA) and polylactic acid (PLA), two biodegradable polymers commonly used in sutures. Bubble structures situated in the patch backing allow the microneedles to penetrate skin under compression, and snap off under shear force within five seconds of patch administration.

Image: Professor Mark Prausnitz holds an experimental microneedle contraceptive skin patch (Photo courtesy of Christopher Moore/Georgia Tech).
Image: Professor Mark Prausnitz holds an experimental microneedle contraceptive skin patch (Photo courtesy of Christopher Moore/Georgia Tech).

The microneedles provide continuous, sustained release of the contraceptive hormone levonorgestrel. In a study in rats, the microneedle patch was well tolerated, leaving little visible evidence of use, and maintained plasma concentrations of the hormone above the human therapeutic level for one month. The researchers suggest that further development of the rapidly separable microneedle patch for self-administered, long-acting contraception could enable women to better control their fertility. The study was published on January 14, 2019, in Nature Biomedical Engineering.

“Our goal is for women to be able to self-administer long-acting contraceptives with the microneedle patch that would be applied to the skin for five seconds just once a month,” said corresponding author Professor Mark Prausnitz, PhD, of Georgia Tech. “We do not yet know how the contraceptive microneedle patches would work in humans. Because we are using a well-established contraceptive hormone, we are optimistic that the patch will be an effective contraceptive.”

Long-acting contraceptives are available in formats such as patches that must be worn continuously, intrauterine devices (IUDs) that must be placed by trained healthcare professionals, and drugs injected with hypodermic needles. If the microneedle contraceptive patch is ultimately approved for use, it could become the first self-administered, long-acting contraceptive that does not involve a conventional needle injection.

Related Links:
Georgia Institute of Technology
University of Michigan


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
LED Phototherapy System
Bililed Mini+

Latest Patient Care News

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput

Next Gen ICU Bed to Help Address Complex Critical Care Needs